Dishman CarbogenQ1 FY25

Dishman Carbogen Q1 FY25 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹130.34Market Cap: ₹2.0K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 3

Margin

Category 1

Fundraise

N/A

Order

N/A

Capex

No

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 3
  • India CRAMS business expected to grow significantly post regulatory clearance, targeting Rs. 325-350 crores revenue for FY 2025, with further growth in subsequent years closer to Rs. 400 crores.
  • Swiss entity anticipated to deliver growth year-over-year on both development and commercial fronts; aiming to exceed CHF 200 million revenue for FY 2025.
  • Overseas entities (Swiss, Dutch, Shanghai, Manchester) have capacity to improve utilization and revenues.
  • French facility, recently started, currently unutilized; expected to ramp up and reduce losses by Q3 FY 2025.
  • Overall group expects about 10% incremental revenue growth over last year.
  • Potential positive impact from global pharma shifts (e.g., sourcing away from China) benefiting European and Indian operations.
  • Maintenance CAPEX expected around Rs. 17-18 million annually; no major growth CAPEX anticipated.

See what Dishman Carbogen management said on margin guidance — free account, 30 seconds.

Fundraise plans

  • No explicit mention of any current or planned new fundraising through debt or equity in the transcript.
  • Net debt as of June 30, 2024, stood at CHF 164 million, with no direct commentary on raising new debt.
  • The company expects to keep CAPEX largely maintenance-focused without significant growth CAPEX, which suggests no immediate large funding needs.
  • There is no indication from management about equity fundraising or debt refinancing plans in the Q&A.
  • Financial strategy seems to focus on improving operating performance and cash flow to manage existing obligations rather than new funding rounds.

See what Dishman Carbogen management said on order book — free account, 30 seconds.

Capex plans

No
  • No significant growth CAPEX is expected in the near future.
  • CAPEX will mainly focus on maintenance and compliance to ensure GMP compliance.
  • Maintenance CAPEX is estimated to be around Rs. 17-18 crores annually.
  • Recent investments include a new French facility worth about €50 million, which has just started generating revenue and is currently underutilized.
  • Potential for revenue increase exists across various group facilities without requiring major new CAPEX.
  • Strategic focus is on improving utilization and operational efficiency rather than large new capital investment.

Track Dishman Carbogen — get its next earnings analysis in your feed

How does Dishman Carbogen rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature
ThisDishman Carbogen
Rev 3Mar 1

How does Dishman Carbogen rank in Pharmaceuticals & Biotechnology?

Compare Dishman Carbogen against every Pharmaceuticals & Biotechnology company (Q1 FY25) on revenue, margins and earnings-call signals.

View Pharmaceuticals & Biotechnology leaderboard →

Others in Pharmaceuticals & Biotechnology this season

  • Lasa Supergeneri (Q2 FY27)

    306.11 Lakhs in Q2 Sept 30, 2025 (over 99% decline YoY). Key results statement takeaways from Lasa Supergenerics Ltd's Q2 FY27 results statement — and how it ra

  • Themis Medicare (Q2 FY27)

    Q2 FY27 net revenue: ₹89.74 crore, up 15.1% year-on-year from ₹77.99 crore in Q2 FY26 (Page 8). Key investor presentation takeaways from Themis Medicare Ltd's Q

  • Panacea Biotec (Q2 FY27)

    September 30, 2026: ₹18,967 Lakh . Key results statement takeaways from Panacea Biotec Ltd's Q2 FY27 results statement — and how it ranks against sector peers.

  • Biofil Chemicals (Q2 FY27)

    Quarterly Revenue (Q2 ended 30/09/2026):** ₹166.87 Lakhs (Pharma Unit), ₹0.00 Lakhs (Chemicals Division); Total Gross Turnover ₹166.87 Lakhs. Key results statem

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →